The price of AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) shares last traded on Wall Street rose 0.13% to $15.00.
Based on available information, 5 analysts follow AVEO Pharmaceuticals Inc. (NASDAQ:AVEO). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $15.00, we find $15.00. Given the previous closing price of $14.98, this indicates a potential upside of 0.13 percent. AVEO stock price is now 0.73% away from the 50-day moving average and 64.90% away from the 200-day moving average. The market capitalization of the company currently stands at $521.10M.
Among analysts, 5 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $15.00 as their price target over the next twelve months.
With the price target maintained at $15, Stifel recently Downgraded its rating from Buy to Hold for AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). On November 09, 2020, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $9, while ‘SVB Leerink’ rates the stock as ‘Outperform’.
Insiders disposed of 43,719,703 shares of company stock worth roughly $655.8 million over the past 1 year. A total of 0.19% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AVEO stock. A new stake in AVEO Pharmaceuticals Inc. shares was purchased by GLOBEFLEX CAPITAL L P during the first quarter worth $5,528,000. EAM GLOBAL INVESTORS LLC invested $3,176,000 in shares of AVEO during the first quarter. In the first quarter, INVESCO LTD. acquired a new stake in AVEO Pharmaceuticals Inc. valued at approximately $2,582,000. ALLIANCEBERNSTEIN L.P. acquired a new stake in AVEO for approximately $1,870,000. CAXTON ASSOCIATES LP purchased a new stake in AVEO valued at around $1,712,000 in the second quarter. In total, there are 68 active investors with 48.10% ownership of the company’s stock.
A candlestick chart of AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) showed a price of $14.99 on Wednesday morning. During the past 12 months, AVEO Pharmaceuticals Inc. has had a low of $3.06 and a high of $14.99. As of last week, the company has a debt-to-equity ratio of 1.34, a current ratio of 2.40, and a quick ratio of 2.30. The fifty day moving average price for AVEO is $14.89 and a two-hundred day moving average price translates $9.10 for the stock.
The latest earnings results from AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.24, beating analysts’ expectations of -$0.28 by 0.04. This compares to -$0.30 EPS in the same period last year. The net profit margin was -30.80% and return on equity was -81.70% for AVEO. The company reported revenue of $30.45 million for the quarter, compared to $15.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 100.68 percent. For the current quarter, analysts expect AVEO to generate $29.55M in revenue.
AVEO Pharmaceuticals Inc.(AVEO) Company Profile
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent’s Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.